BSC, MSC, Director, BD, Licensing & IP,
Hugh Wellman is currently the Director, BD, Licensing and IP at GenomeDx and has been with the company since 2013. His responsibilities include, business development, licensing with both academic and commercial partners and management of the IP portfolio. Recent notable transactions include a companion diagnostic project with Astellas, and exclusive distribution deals with both Color Genomics and Pathnostics. He has spent the last 10 years working with venture capital funded biotech companies. Before GenomeDx he worked at Sirius Genomics, a commercially focused, pharmacogenomics company. While working with Sirius he built a SNP selection pipeline, managed 3 major genotyping initiatives and was the scientific lead in the largest pharmacogenomic trial ever completed in sepsis. Wellman has played a key role at both companies in establishing broad strategic partnerships and licensing arrangements with pharma/biotech companies and academic institutions for the purpose of biomarker discovery, services and commercialization. Hugh received his undergrad and MSc in Genetics at the University of British Columbia.
Presentation Title and Company Description
Genomic Profiling Showcase: Diagnostics and Big Data
GenomeDx is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes. The company currently offers Decipher genomic tests for prostate and bladder cancer and is using machine learning to develop new offerings through its innovative technology platform.